Filana Therapeutics (FLNA) Share-based Compensation (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Share-based Compensation of $13.7 million for Q2 2026, up 199.0% year-over-year from $4.6 million in Q2 2025, and up 238.02% quarter-over-quarter from $4.1 million in Q1 2026.
Filana Therapeutics (FLNA) Share-based Compensation (2010 - 2026) Analysis & Trends
Filana Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $13.7 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 199.0% year-over-year to $13.7 million; the TTM figure through Jun 2026 stood at $13.7 million (down 35.14% YoY), while the FY2025 annual figure was $24.5 million, down 51.58% from the prior year.
- Share-based Compensation for Q2 2026 stood at $13.7 million, up from $4.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.7 million in Q2 2026, with the low at $462000.0 in Q2 2022.
- The 5-year median for Share-based Compensation is $2.4 million (2024), against an average of $3.3 million.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 47000.0% in 2022, then retreated 21.89% in 2026.
- Filana Therapeutics' Share-based Compensation stood at $616000.0 in 2022, then soared by 245.62% to $2.1 million in 2023, then soared by 169.8% to $5.7 million in 2024, then slipped by 6.44% to $5.4 million in 2025, then soared by 154.93% to $13.7 million in 2026.
- Business Quant data shows FLNA's Share-based Compensation at $13.7 million in Q2 2026, $4.1 million in Q1 2026, and $5.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | - |
| 10 | Filana Therapeutics | 46.27 Mn | 46.27 Mn | - | 13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.70 Mn |
| Jun 30, 2026 | 13.70 Mn |
| Mar 31, 2026 | 4.05 Mn |
| Mar 31, 2026 | 4.05 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 4.58 Mn |
| Mar 31, 2025 | 5.19 Mn |
| Mar 31, 2025 | 5.19 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Sep 30, 2024 | 5.61 Mn |
| Sep 30, 2024 | 5.61 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.31 Mn |